Velicept Therapeutics
Malvern, US · Founded 2015 · Delaware corporation · 2 known investors
Founders & leadership
Board
SM
Scott MorensteinBoard director
DH
David HirschBoard director
JB
James BennethumBoard director
ST
Stephen TullmanBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$39.9M disclosed across 3 rounds · 2015–2019
▶$6MraisedNov 2019 · 5 investors · BiotechnologyRule 506(b)
▶$6MraisedNov 2019 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Scott MorensteinDirector
- Doug GesslExecutive Officer
- David Hirsch, M.D.Director
- Jill Becker MastDirector
- Stephen TullmanDirector
- Aidan King, MBA, CFADirector
- Cory S. FreedlandDirector
- James C. WalkerExecutive Officer, Director
- Offering amount
- $9.2M
- Amount sold
- $6M
- Minimum investment
- $1
- Proceeds to insiders
- $400K
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$15.5MraisedJul 2018 · 16 investors · PharmaceuticalsRule 506(b)
▶$15.5MraisedJul 2018 · 16 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Aidan KingDirector
- James BennethumDirector
- Douglas GesslExecutive Officer
- David HirschDirector
- Scott MorensteinDirector
- James WalkerExecutive Officer, Director
- Cory FreedmanDirector
- Stephen TullmanDirector
- Offering amount
- $15.6M
- Amount sold
- $15.5M
- Proceeds to insiders
- $850K
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$18.4MraisedApr 2017 · 25 investors · PharmaceuticalsRule 506(b)
▶$18.4MraisedApr 2017 · 25 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Scott MorensteinDirector
- James BennethumDirector
- Douglas GesslExecutive Officer
- James WalkerExecutive Officer, Director
- David HirschDirector
- Stephen TullmanDirector
- Offering amount
- $26.3M
- Amount sold
- $18.4M
- Minimum investment
- $4.5K
- Sales commissions
- $1.3M
- Proceeds to insiders
- $750K
- Placement agents
- William Blair & Company, MTS Securities, LLC
- First sale
- Nov 2015
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who are Velicept Therapeutics's investors?
- Velicept Therapeutics's investors include Longitude Capital, Samsara BioCapital.
- How much funding has Velicept Therapeutics raised?
- Velicept Therapeutics has disclosed $39.9M raised across 3 rounds.
- Where is Velicept Therapeutics headquartered?
- Velicept Therapeutics is headquartered in Malvern, US.